Literature DB >> 24463828

Risk factors and time-trends of cytomegalovirus (CMV), syphilis, toxoplasmosis and viral hepatitis infection and seroprevalence in human immunodeficiency virus (HIV) infected patients.

Raymond Bt Lim1, Mei Ting Tan, Barnaby Young, Cheng Chuan Lee, Yee Sin Leo, Arlene Chua, Oon Tek Ng.   

Abstract

INTRODUCTION: Chronic bacterial, viral and parasitic infections contribute to the morbidity and mortality associated with human immunodeficiency virus (HIV) infection. This study investigated risk factors and time-trends of the seroprevalence of cytomegalovirus (CMV), toxoplasmosis and hepatitis A total antibody; and co-infection with syphilis, hepatitis B and hepatitis C among newly diagnosed HIV individuals in Singapore.
MATERIALS AND METHODS: This was a cross-sectional study. A random sample of 50% of HIV infected patients who visited the Communicable Disease Centre (CDC), Singapore for first-time care from January 2006 to December 2011 were analysed.
RESULTS: Among the 793 study subjects, 93.4% were male; 77.9% of them were of Chinese ethnicity; mean age at HIV diagnosis was 41.4 years; and the mean baseline CD4+ T-cell count was 222 cells/mm³. The prevalence of sero-reactivity for CMV was 96.8%; hepatitis A: 40.9%; and toxoplasmosis: 23.7%. Co-infection with syphilis was identified in 12.3%; hepatitis B: 8.1%; and hepatitis C: 2%. Among those co-infected with hepatitis C, 73.3% of them were intravenous drug user (IVDU). Syphilis co-infection was significantly more common among men who have sex with men (MSM) (multivariate OR: 2.53, 95% CI, 1.31 to 4.90, P = 0.006).
CONCLUSION: This study described the baseline rates of HIV co-infection with syphilis, hepatitis B and C in Singapore, and sero-reactivity to CMV, toxoplasmosis and hepatitis A. The increased rates compared to the general population may have important consequences for disease progression, response to antiretroviral treatment and long-term general health.

Entities:  

Mesh:

Year:  2013        PMID: 24463828

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  6 in total

1.  Shortness of breath in a patient with inflammatory bowel disease.

Authors:  Aoife Abbey; Amy C Elsmore
Journal:  BMJ Case Rep       Date:  2014-10-09

2.  What are the factors associated with human immunodeficiency virus/sexually transmitted infection screening behaviour among heterosexual men patronising entertainment establishments who engaged in casual or paid sex? - Results from a cross-sectional survey in an Asian urban setting.

Authors:  Raymond Boon Tar Lim; Dede Kam Tyng Tham; Olive N Y Cheung; Bee Choo Tai; Roy Chan; Mee Lian Wong
Journal:  BMC Infect Dis       Date:  2016-12-19       Impact factor: 3.090

Review 3.  Seroprevalence of ToRCH Pathogens in Southeast Asia.

Authors:  Franziska E Fuchs; Maude Pauly; Antony P Black; Judith M Hübschen
Journal:  Microorganisms       Date:  2021-03-11

4.  Sequencing Directly from Clinical Specimens Reveals Genetic Variations in HCMV-Encoded Chemokine Receptor US28 That May Influence Antibody Levels and Interactions with Human Chemokines.

Authors:  Shelley Waters; Mark Agostino; Silvia Lee; Ibnu Ariyanto; Nina Kresoje; Shay Leary; Kylie Munyard; Silvana Gaudieri; Jessica Gaff; Ashley Irish; Anthony D Keil; Patricia Price; Richard J N Allcock
Journal:  Microbiol Spectr       Date:  2021-10-27

5.  Derivation and validation of an accurate estimation of CD4 counts from the absolute lymphocyte count in virologically suppressed and immunologically reconstituted HIV infected adults.

Authors:  Barnaby Young; Oon Tek Ng; David Chien Lye; Yee Sin Leo
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

6.  Emergence of Cytomegalovirus Mononucleosis Syndrome Among Young Adults in Hong Kong Linked to Falling Seroprevalence: Results of a 14-Year Seroepidemiological Study.

Authors:  Siddharth Sridhar; Tom W H Chung; Jasper F W Chan; Vincent C C Cheng; Susanna K P Lau; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  Open Forum Infect Dis       Date:  2018-10-20       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.